CASE REPORT. Abstract. Introduction. Case Reports
|
|
- Ashlee Higgins
- 5 years ago
- Views:
Transcription
1 CASE REPORT Efficacy of Early Intravenous Immunoglobulin for Eosinophilic Granulomatosis with Polyangiitis with Drastically Progressive Neuropathy: A Synopsis of Two Cases Takeshi Matsumoto 1, Kojiro Otsuka 1, Michi Kawamoto 2, Kazuma Nagata 1, Ryo Tachikawa 1, Yukihiro Imai 3, Nobuyuki Oka 4 and Keisuke Tomii 1 Abstract Two women, 66-year-old and 63-year-old, were admitted for drastically progressive neuropathy, and diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA). Steroid pulse therapy failed to exert effect upon neuropathy, so we administered early intravenous immunoglobulin (IVIG) for fear of immobilization of neuropathy. This resulted in marked improvement in neuropathy without apparent side effects. Recent evidence suggests the efficacy of IVIG for steroid refractory neuropathy associated with EGPA, but has previously been administered during the chronic phase resulting in slow improvement. Our two successfully treated cases indicate the efficacy of early IVIG in preventing the immobilization of neuropathy, especially in progressive cases. Key words: eosinophilic granulomatosis with polyangiitis (EGPA), Churg-Strauss syndrome (CSS), intravenous immunoglobulin (IVIG), neuropathy, early administration (Intern Med 52: , 2013) () Introduction Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome (CSS), is characterized by the presence of asthma, hypereosinophilia and small-to medium-sized vessel vasculitis with granuloma (1). Peripheral neuropathy, usually mononeuritis multiplex, is seen in up to 75 percent of patients with EGPA (2). For the treatment of EGPA, systemic steroids are the predominant choice, and the majority of EGPA patients respond well to such treatment. However, some patients suffer from neuropathy refractory to steroid treatment resulting in a marked and longstanding reduction in the ability to perform ADLs. Recently, the efficacy of intravenous immunoglobulin (IVIG) in treating the neuropathy of EGPA has been reported; however, the administration of such treatment is generally considered in the chronic phase, usually more than four weeks after the first administration of steroids, resulting in only a slow improvement in neuropathy. Since EGPA involves aspects of ischemic disorders, it is important to treat such cases as quickly as possible in the acute phase, especially rapidly progressive cases, before fixed neuropathy becomes established. We herein report two cases of EGPA with drastically progressive neuropathy refractory to steroids that were successfully treated with the early administration of IVIG in addition to steroids. Case 1 Case Reports A 66-year-old woman diagnosed with EGPA was admitted to our hospital due to drastically progressive neuropathy. Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Japan, Department of Neurology, Kobe City Medical Center General Hospital, Japan, Department of Clinical Pathology, Kobe City Medical Center General Hospital, Japan and Department of Neurology, Minami-Kyoto National Hospital, Japan Received for publication August 30, 2012; Accepted for publication January 11, 2013 Correspondence to Dr. Takeshi Matsumoto, t.matsumoto@kcho.jp 913
2 Figure 1. (a) Purpura on the left lower leg in case 1. (b) The result of purpura biopsy with Giemsa stain shows eosinophilic infiltration in extravascular areas. (c) Hematoxylin and Eosin (H&E) staining shows eosinophilic infiltration in extravascular areas. (d) The result of sural nerve biopsy in case 2 with H&E staining shows occlusion of epineurium vessel (arrow), with mononuclear cell infiltration. (e) CD68 staining shows macrophage infiltration. (f) Toluidine blue staining shows broad axonal degeneration of internal sheath of nerve. She had been treated for uncontrolled bronchial asthma for three years. One year before admission, she noticed plantar paresthesia, which gradually worsened for one month prior to admission. The paresthesia rapidly progressed, extending to the extremities, and muscle weakness appeared in the patient s left arm three days before admission. Since the symptoms drastically progressed and the patient became unable to stand, she was conveyed by ambulance to our emergency unit. On physical examination, she exhibited purpura on her left lower leg (Fig. 1a). No abnormalities were found in the chest or abdomen. Neurological examinations showed muscle weakness of the left arm and fingers, with a score of 2 on a manual muscle test (MMT), and the lower legs, with a score of 4 on the MMT, in addition to deep sensation disturbance, particularly on both soles, that prevented the patient from standing. Chest radiography showed no abnormalities. Laboratory studies revealed the following values: white blood cell count, 36,000/mm 3 with 70% eosinophils; C- reactive protein, 3.8 mg/dl; myeloperoxidase-specific antineutrophil cytoplasmic antibody ( MPO-ANCA) and proteinase-3 specific antineutrophil cytoplasmic antibody (PR3-ANCA), negative; immunoglobulin E (IgE), 3,574 U/ ml; and occult blood in urine, 5-9/high-power field (HPF). A skin biopsy of the purpura disclosed eosinophilic infiltration around the capillary vessels, indicating vasculitis (Fig. 1b, c). The patient therefore fulfilled the American College of Rheumatology (ACR) criteria for CSS with a history of asthma, hypereosinophilia, mononeuritis multiplex and histological evidence of eosinophilic infiltration in extravascular areas (3). We commenced steroid pulse therapy (methylprednisolone (mpsl), 500 mg for three days) on the day of admission, followed by mpsl at a dose of 80 mg daily. Although the patient s subjective view of muscle weakness slightly improved, the MMT scores did not change. In addition, no differences were observed in sensory disturbance, and the patient was unable to stand alone. For fear of future impending reductions in the QOL as a result of immobilization due to neuropathy, we administered IVIG at a dose of 400 mg/ kg/day for five days starting on day 5. The deep sensation disturbance improved quickly, and the patient was able to stand on day 8. The muscle weakness in the left arm also gradually improved, and the patient was able to walk with a walker on day 14. However, improvements in paresthesia in both soles achieved a plateau, and during the course of treatment, the paresthesia slightly deteriorated on day 29. A nerve conduction test performed on day 31 showed axonal changes (Table 1). Since the first course of IVIG was effective, we administered a second course of IVIG on day 36. The paresthesia and muscle weakness subsequently improved, enabling the patient to walk alone without a walker on day 43. The MMT scores of the left arm and fingers ultimately improved from 2 to 4 +. The patient was discharged on day 62 (Fig. 2). Case 2 A 63-year-old woman who was treated for bronchial asthma for 23 years first noticed a steppage gait and paresthesia in her left lower leg three years before admission. These symptoms fluctuated but gradually worsened. She noticed paresthesia of both soles one month before admission, and found it difficult to walk one week before admission. She was admitted to our hospital for further investigation. 914
3 Table 1. A Nerve Conduction Test in Case 1 Figure 2. Clinical course of case 1. IgE: Immunoglobulin E, IVIG: intravenous immunoglobulin, mpsl: methylprednisolone, MMT: manual muscle test Table 2. A Nerve Conduction Test in Case 2 On physical examination, no abnormalities were found in the chest, abdomen or skin. Neurological examinations showed muscle weakness in both lower legs, with MMT scores of 2; however, the MMT scores of the proximal muscles were 5. Severe deep sensation disturbance was seen, particularly in both legs, which prevented the patient from standing. Laboratory studies showed the following values: white blood cell count, 15,100/mm 3 with 49% eosinophils; C-reactive protein, 1.2 mg/dl; MPO-ANCA and PR3- ANCA, negative; IgE, 692 U/mL; and occult blood in urine, 0-1/HPF. A sural nerve biopsy was performed on day 5, which showed infiltration of mononuclear cells within the vessel walls and around the capillaries, indicating vasculitis. The infiltrates were composed of macrophages and lymphocytes. Most of the myelinated fibers exhibited axonal degeneration (Fig. 1d, e, f). Although no eosinophilic infiltration was seen, most likely due to the administration of steroids before the nerve biopsy, we diagnosed the patient with EGPA on the grounds of the above findings. A nerve conduction test performed on day 15 showed axonal changes Figure 3. Clinical course of case 2. IgE: Immunoglobulin E, IVIG: intravenous immunoglobulin, mpsl: methylprednisolone, MMT: manual muscle test (Table 2). In this case, we also started steroid pulse therapy (mpsl, 500 mg for three days) followed by mpsl at a dose of 80 mg daily for drastically progressive neuropathy. The muscle power of the patient s lower legs and the deep sensation disturbance did not exhibit a prompt response to steroid treatment, preventing the patient from standing. Therefore, we administered IVIG at a dose of 400 mg/kg/day for five days starting on day 13. The paresthesia and deep sensation disturbance gradually improved, enabling the patient to stand on day 17, walk with a walker on day 23 and walk alone on day 36. The MMT scores of both lower legs improved from 2 to 4. The patient was discharged on day 38 (Fig. 3). Discussion The first step in the management of EGPA is to assess the disease severity according to the five-factors score based on 915
4 the presence of five clinical factors: gastrointestinal disorders, renal dysfunction, severe proteinuria, myocardial disorders and central nerve system disorders, all of which are associated with the poor prognosis of EGPA (4). Although not strongly associated with mortality, peripheral neuropathy is closely related to the QOL and often remains unimproved (5). The principle of treatment of EGPA is to provide early diagnosis and treatment. Steroids are the mainstay of treatment for EGPA. Although over half of patients exhibit immediate improvements following the administration of steroids, other cases are refractory (6). For patients with severe multiorgan disease, especially those with poor prognosis factors, cyclophosphamide is typically used in combination with steroids (7). Despite the use of combination therapy, a large proportion of patients with EGPA suffer from long-lasting neuropathies that lead to a marked reduction in the ability to perform ADLs. In addition, cyclophosphamide causes serious adverse effects such as hemorrhagic inflammation of the bladder, testicular and ovary dysfunction, myelosuppression, carcinogenicity and so on. As mentioned above, the neuropathy caused by EGPA is often refractory to steroid therapy. Hattori et al. reported that approximately 57% of patients with EGPA exhibit no response, even after four weeks of steroid administration, thus resulting in a long-lasting poor function (8). Recently, the efficacy of IVIG for treating neuropathy of EGPA refractory to steroids has been reported (9), and the drug has been revealed to exhibit steroid-sparing effects (10, 11). IVIG demonstrates efficacy in treating the neuropathy of EGPA in the chronic phase that is refractory to long-term steroid treatment (12). Danieli et al. reported that, in their study, while 44% of patients receiving steroids and cyclophosphamide achieved remission in neuropathy, all patients receiving IVIG and plasmapheresis achieved remission in neuropathy (13). The clinical backgrounds associated with the efficacy of IVIG involve pretreatment with steroids and immunosuppressants before the administration of IVIG. In addition, it has been reported that when IVIG is effective on the first administration, re-administration may also be effective; however, when the first administration of IVIG is ineffective, re-administration may also be ineffective (12). Generally, IVIG is administered during the chronic phase, predominantly starting four weeks after the first administration of steroids, thus resulting in a slow improvement of neuropathy. Since EGPA exhibits aspects of ischemic disorders, it is important to treat the condition as quickly as possible during the acute phase, especially in rapidly progressive cases, before fixed neuropathy is established, as regeneration of peripheral nerves may require months or years (12). Our two patients with drastically progressive neuropathy were first treated with steroid pulse therapy. Cyclophosphamide was not given to either patient since the fivefactors score was zero in both cases. Although rapid progression of neuropathy was retarded by steroid treatment, no further improvements were observed, leaving both patients with an impaired ability to perform ADLs. Therefore, we administered IVIG on day 5 and day 13, respectively, resulting in marked improvement of neuropathy without any apparent side effects. Due to remaining neuropathy, our first patient required a second course of IVIG, which also improved the neuropathy. One year and a half after discharge, both patients were reviewed in our hospital, and no relapse of neuropathy was observed in either case. The contribution of continuous steroid administration to the observed improvements in neuropathy cannot be ruled out. However, for both patients, the symptoms of neuropathy were apparently altered after the administration of IVIG. Furthermore, our first patient not only showed improvement of neuropathy after the first administration of IVIG, but also demonstrated further improvement after a plateau following the second administration of IVIG, which suggests the beneficial effects of IVIG on neuropathy. Considering the patients clinical courses, it seems that IVIG combination therapy played a pivotal role in the improvement of neuropathy in these cases. To the best of our knowledge, there are few case reports of the efficacy of early administration of IVIG treatment for the neuropathy of EGPA. Of the few cases, many are in the form of conference abstracts. Our two cases are valuable because the patients exhibited improvement of drastically progressive neuropathy in response to the early administration of IVIG in combination with steroids. In conclusion, early treatment with IVIG in combination with steroids during the acute phase of EGPA neuropathy may be effective, especially in rapidly progressive cases, and may prevent the establishment of fixed neuropathy. Further studies are needed to clarify the therapeutic efficacy of IVIG during the acute phase of EGPA neuropathy and to determine the optimal timing of administration. The authors state that they have no Conflict of Interest (COI). References 1. Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener s): an alternative name for Wegener s granulomatosis. Arthritis Rheum 63: , Wolf J, Bergner R, Mutallib S, Buggle F, Grau AJ. Neurologic complications of Churg-Strauss syndrome: a prospective monocentric study. Eur J Neurol 17: , Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33: , Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term followup of 96 patients. Medicine (Baltimore) 78: 26-37, Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg- Strauss syndrome. Arthritis Rheum 52: , Guillevin L, Pagnoux C. Therapeutic strategies for systemic necrotizing vasculitides. Allergol Int 56: , Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg-strauss syndrome in patients treated with omalizumab. 916
5 Chest 136: , Hattori N, Ichimura M, Nagamatsu M, et al. Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain 122: , Hamilos DL, Christensen J. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. J Allergy Clin Immunol 88: , Tsurikisawa N, Taniguchi M, Saito H, et al. Treatment of Churg- Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 92: 80-87, Kobayashi D, Wada Y, Takata T, et al. A severe form of Churg- Strauss syndrome complicated with acute cardiac failure and rapidly progressive peripheral neuropathy: a possible effect of intravenous immunoglobulin therapy. Intern Med 50: , Taniguchi M, Tsurikisawa N, Higashi N, et al. Treatment for Churg-Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy. Allergol Int 56: , Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis 63: , The Japanese Society of Internal Medicine 917
Title. CitationClinical Neurology and Neurosurgery, 111(8): Issue Date Doc URL. Type. File Information
Title Clinical characterization and successful treatment o Nakamura, Masakazu; Yabe, Ichiro; Yaguchi, Hiroaki; Author(s) Hideki; Tsuji-Akimoto, Sachiko; Niino, Masaaki; Sasa CitationClinical Neurology
More informationVasculitis local: systemic
Vasculitis Inflammation of the vessel wall. Signs and symptoms: 1- local: according to the involved tissue 2- systemic:(fever, myalgia, arthralgias, and malaise) Pathogenesis 1- immune-mediated 2- infectious
More informationBowel perforations in a patient affected by Churg-Strauss syndrome under high-dose steroid treatment: will alternative drugs reduce risk of surgery?
Bowel perforations in a patient affected by Churg-Strauss syndrome under high-dose steroid treatment: will alternative drugs reduce risk of surgery? Dario Venditti, Balassone Valerio, Benedetto Ielpo,
More informationJCN Open Access INTRODUCTION ORIGINAL ARTICLE
JCN Open Access pissn 1738-6586 / eissn 2005-5013 / J Clin Neurol 2017;13(1):77-83 / https://doi.org/10.3988/jcn.2017.13.1.77 ORIGINAL ARTICLE Clinical Characteristics and Treatment Response of Peripheral
More informationRituximab treatment for ANCA-associated vasculitis in childhood
Rituximab treatment for ANCA-associated vasculitis in childhood DISCLOSURE I have no relevant financial relationships to disclose Katharine Moore MD Nov 14, 2012 University of Colorado School of Medicine
More informationDecember 6, 2010 Asthma and Rheumatic Disorders and Vasculitis
December 6, 2010 Asthma and Rheumatic Disorders and Vasculitis Lanny J. Rosenwasser, M.D. Dee Lyons/Missouri Endowed Chair in Immunology Research Professor of Pediatrics Allergy-Immunology Division Childrens
More informationDr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology
Vasculitis Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology Disease Spectrum Hypersensitivity vasculitis/microscopic
More informationVasculitis local: systemic
Vasculitis Inflammation of the vessel wall. Signs and symptoms: 1- local: according to the involved tissue 2- systemic:(fever, myalgia, arthralgias, and malaise) Pathogenesis 1- immune-mediated inflammation
More informationPAEDIATRIC VASCULITIS
PAEDIATRIC VASCULITIS Lawrence Owino Okong o, Mmed (UoN); Mphil. (UCT). Lecturer, Department of Paediatrics and Child Health, University of Nairobi. Paediatrician/ Rheumatologist. OUTLINE Introduction
More informationSHO Teaching. Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth
SHO Teaching Vasculitis Renal medicine Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth OUTLINE What is vasculitis Causes Classification Brief look into ANCA Associated Vasculitis (AAV)
More informationElevated Expression of Pentraxin 3 in Anti-neutrophil Cytoplasmic Antibody-associated Glomerulonephritis with Normal Serum C-reactive Protein
CASE REPORT Elevated Expression of Pentraxin 3 in Anti-neutrophil Cytoplasmic Antibody-associated Glomerulonephritis with Normal Serum C-reactive Protein Risa Ishida 1,KentaroNakai 1, Hideki Fujii 1, Shunsuke
More informationPharmacy Management Drug Policy
SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes
More informationB. Sokołowska, W. Szczeklik, A. Włudarczyk, P. Kuczia, B. Jakieła, J. Gąsior, S. Bartyzel, P. Rewerski, J. Musiał
ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish centre B. Sokołowska, W. Szczeklik,
More informationAtlas of the Vasculitic Syndromes
CHAPTER e40 Atlas of the Vasculitic Syndromes Carol A. Langford Anthony S. Fauci Diagnosis of the vasculitic syndromes is usually based upon characteristic histologic or arteriographic findings in a patient
More informationOBSERVATION. Initial Cutaneous Manifestations Consistent With Mononeuropathy Multiplex in Churg-Strauss Syndrome
OBSERVATION Initial Cutaneous Manifestations Consistent With Mononeuropathy Multiplex in Churg-Strauss Syndrome Tamihiro Kawakami, MD, PhD; Yoshinao Soma, MD, PhD; Kanade Kawasaki, MD; Ayumi Kawase, MD;
More informationVasculitis. Edward Dwyer, M.D. Division of Rheumatology. Vasculitis
Edward Dwyer, M.D. Division of Rheumatology VASCULITIS is a primary inflammatory disease process of the vasculature Determinants of the Clinical Manifestations of : Target organ involved Size of vessel
More informationVasculitis of the peripheral nervous system
4 rd Congress of the European Academy of Neurology Lisbon, Portugal, June 16-19, 2018 Teaching Course 5 Acute emergencies in neuromuscular disease - Level 2 Vasculitis of the peripheral nervous system
More informationanti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide, corticosteroid
Online publication June 24, 2009 ANCA JMAAV 1 2 ANCA JMAAV MPO-ANCA 18 17 50 J Jpn Coll Angiol, 2009, 49: 53 61 anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide,
More informationVASCULITIS. Case Presentation. Case Presentation
VASCULITIS Case Presentation The patient is a 24 year old woman who presented to the emergency room with left-sided weakness. She was confused and complained of a severe headache. She was noted to have
More informationClinical analysis of nervous system involvement in ANCA-associated systemic vasculitides
Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides W. Zhang, G. Zhou*, Q. Shi, X. Zhang, X.-F. Zeng, F.-C. Zhang Department of Rheumatology, Peking Union Medical College
More informationCase Presentation VASCULITIS. Case Presentation. Case Presentation. Vasculitis
Case Presentation VASCULITIS The patient is a 24 year old woman who presented to the emergency room with left-sided weakness. She was confused and complained of a severe headache. She was noted to have
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Update on Granulomatosis with Polyangiitis (Wegener s) Learning Objectives Identify the clinical features of granulomatosis with
More informationRate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a meta-analysis
Rate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a meta-analysis M. Jung 1, L. Barra 2 1 Division of Rheumatology, Department of Medicine, University
More informationAN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS
GRANULOMATOSIS WITH POLYANGIITIS (GPA), MICROSCOPIC POLYANGIITIS (MPA), and EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS What is ANCA-associated Vasculitis?
More informationMohammad Reza Shakibi M.D Kerman university of medical sciences (KMU) Shafa Hospital, Rheumatology ward
VASCULITIS SYNDROMES Mohammad Reza Shakibi M.D Kerman university of medical sciences (KMU) Shafa Hospital, Rheumatology ward ILLUSTRATED CASE 1 A 56 years old lady refered me for prolonged fever, arthritis
More informationRenal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis
Renal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis E.S. Park, S.S. Ahn, S.M. Jung, J.J. Song, Y.-B. Park, S.-W. Lee Division of Rheumatology, Department of Internal
More informationEDITORIAL. Issue Seventeen, October Editorial Team. Issue Seventeen. Info link
EDITORIAL, October 2004 Welcome to the Spring 2004 Edition of InfoLink. The feature article in this edition has been written by Dr Rodger Laurent, Head of Department, PaLMS Rheumatology Laboratory. The
More informationC hurg-strauss syndrome (CSS) is a necrotising vasculitis
1649 EXTENDED REPORT Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome M G Danieli, M Cappelli, G Malcangi, F Logullo, A Salvi, G Danieli... See end of article for authors
More informationHOW TO ADDRESS THE CHALLENGES AND MAXIMISE PATIENT OUTCOMES IN THE ASSESSMENT AND MANAGEMENT OF AUTOIMMUNE DISEASE?
HOW TO ADDRESS THE CHALLENGES AND MAXIMISE PATIENT OUTCOMES IN THE ASSESSMENT AND MANAGEMENT OF AUTOIMMUNE DISEASE? Amy Szuman HYMS YEAR 4 MEDICAL STUDENT INTRODUCTION AND PATIENT EXPERIENCE Autoimmune
More informationANCA+ VASCULITIDES CYCAZAREM,
ANCA+ VASCULITIDES CYCAZAREM, q Comparison of 3 to 6 mo. oral CYC + CS then azathioprine or oral CYC for 12 mo.+ 10 mg/d CS. After 12 mo all the patients were treated with azathioprine q 150 patients followed
More informationReview Article. Current concepts in Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis. Milind Aurangabadkar
Review Article Vidarbha Journal of Internal Medicine Volume 23 July 207 Current concepts in Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis Milind Aurangabadkar ABSTRACT Anti-neutrophil
More informationCase Rep Nephrol Urol 2013;3: DOI: / Published online: January 27, 2013
Published online: January 27, 2013 1664 5510/13/0031 0016$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license),
More informationSmall Vessel Vasculitis
Banff- Rocky Mountain Barry Kassen, MD, FRCPC,FACP Head, Division of Internal Medicine UBC/VGH/SPH Acting Head, Division of Community Internal Medicine November, 2009 Objectives 1. To understand small
More informationSmall Vessel Vasculitis
Small Vessel Vasculitis Paul A Brogan Professor of Vasculitis and Consultant Paediatric Rheumatologist Department of Rheumatology Institute of Child Health and Great Ormond St Hospital, London UK P.brogan@ucl.ac.uk
More informationMicroscopic polyangiitis complicated with ileal involvement detected by double-balloon endoscopy: a case report
Fukushima et al. BMC Gastroenterology 2013, 13:42 CASE REPORT Open Access Microscopic polyangiitis complicated with ileal involvement detected by double-balloon endoscopy: a case report Masashi Fukushima
More informationManagement of Acute Vasculitis. CMT teaching 3 rd June 2015 Caroline Wroe
Management of Acute Vasculitis CMT teaching 3 rd June 2015 Caroline Wroe Vasculitis pub quiz Match the date with the event Dr Peter McBride, Scottish Otolaryngologist describes a disease of rapid destruction
More informationManaging Acute Medical Problems, Birmingham Vasculitis. David Jayne. University of Cambridge
Managing Acute Medical Problems, Birmingham 2016 Vasculitis David Jayne University of Cambridge Disclosures Astra Zeneca, Aurinia, BIOGEN, Boehringer, Chemocentryx, Genzyme/Sanofi, GSK, Lilly, Medimmune,
More informationReviews in Clinical Medicine
Mashhad University of Medical Sciences (MUMS) Reviews in Clinical Medicine Clinical Research Development Center Ghaem Hospital Churg-Strauss Syndrome in a Seven-year-old Boy: A Case Report Abdolreza Malek
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus
More informationPlasma exchanges in ANCA-associated vasculitis
Plasma exchanges in ANCA-associated vasculitis Xavier Puéchal, MD, PhD Centre de Référence des Maladies auto-immunes systémiques rares d Ile de France Hôpital Cochin Université Paris Descartes http://www.vascularites.org
More informationSMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018
SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018 OUTLINE Renal involvement in vasculitis Curr Rheumatol Rep 2013 Renal involvement in ANCA vasculitis GN***:
More informationProtocol Version 2.0 Synopsis
Protocol Version 2.0 Synopsis Title Short Title Plasma exchange and glucocorticoid dosing in anti-neutrophil cytoplasm antibody associated vasculitis: a randomized controlled trial. PEXIVAS PEXIVAS Clinical
More informationTREATMENT OF ANCA-ASSOCIATED VASCULITIS
TREATMENT OF ANCA-ASSOCIATED VASCULITIS Loïc Guillevin Hôpital Cochin, Université Paris Descartes Cours DU, 11 mars 2016 1 Disclosure of interest regarding this presentation Roche has provided, in part,
More informationCombined Allergic Bronchopulmonary Aspergillosis and Eosinophilic Granulomatosis with Polyangiitis: Three Cases and a Review of the Literature
CASE REPORT Combined Allergic Bronchopulmonary Aspergillosis and Eosinophilic Granulomatosis with Polyangiitis: Three Cases and a Review of the Literature Takashi Ishiguro, Noboru Takayanagi, Yotaro Takaku,
More informationChurg Strauss syndrome
http://www.kidney-international.org & 2009 International Society of Nephrology Churg Strauss syndrome Augusto Vaglio 1, Ines Casazza 1, Chiara Grasselli 1, Domenico Corradi 2, Renato A. Sinico 3 and Carlo
More informationClinical and pathological features of Churg Strauss syndrome among a Japanese population: a case series of 18 patients
Original article Clinical and pathological features of Churg Strauss syndrome among a Japanese population: a case series of 18 patients Tatsunori Shimoi, Kensaku Shojima, Atsuko Murota, Yasunobu Takizawa,
More informationPresenting Features in Pakistani Patients Suffering from the Antineutrophil Cytoplasmic Antibody - Classical Subtype (c- ANCA) Associated Vasculitis
Presenting Features in Pakistani Patients Suffering from the Antineutrophil Cytoplasmic Antibody - Classical Subtype (c- ANCA) Associated Vasculitis Tahir Aziz Ahmed,Abdul Halim,Tassawar Hussain,Nadeem
More informationEULAR/ERA-EDTA recommendations for the management of ANCAassociated
EULAR/ERA-EDTA recommendations for the management of ANCAassociated vasculitis Dr. Meharunnisha Syed III year DNB Resident (General Medicine) Narayana Health-MSH Fifteen recommendations were developed,
More informationSinonasal involvement in systemic vasculitides and cocaine-induced midline destructive lesions: Diagnostic controversies
Sinonasal involvement in systemic vasculitides and cocaine-induced midline destructive lesions: Diagnostic controversies M. Armengot, M.D., Ph.D., A. García-Lliberós, M.D., M. J. Gómez, M.D., A. Navarro,
More informationTell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital
Tell me more about vasculitis Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital Talk overview Case study ANCA-associated vasculitis What is ANCA vasculitis? What causes ANCA
More informationW egener s granulomatosis (WG), Churg Strauss syndrome
PAPER Peripheral neuropathy in Wegener s granulomatosis, Churg Strauss syndrome and microscopic polyangiitis Luigi Cattaneo, Elisabetta Chierici, Laura Pavone, Chiara Grasselli, Paolo Manganelli, Carlo
More informationSeven cases of complete and incomplete forms of Churg-Strauss syndrome not related to leukotriene receptor antagonists
Seven cases of complete and incomplete forms of Churg-Strauss syndrome not related to leukotriene receptor antagonists Androniki Bili, MD, a John J. Condemi, MD, a Susan M. Bottone, MD, c and Charlotte
More informationRAPIDLY FAILING KIDNEYS. Dr Paul Johny 2 nd yr DNB Medicine Resident
RAPIDLY FAILING KIDNEYS Dr Paul Johny 2 nd yr DNB Medicine Resident Mr Z 67yrs old Occupation : Retired officer from electricity board Chief complaints : Fever : 5 days Right lower limb swelling and pain
More informationRATIONALE. K Without therapy, ANCA vasculitis with GN is associated. K There is high-quality evidence for treatment with
http://www.kidney-international.org chapter 13 & 2012 KDIGO Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis Kidney International Supplements (2012) 2, 233 239; doi:10.1038/kisup.2012.26
More informationAUTOIMMUNE DISORDERS IN THE ACUTE SETTING
AUTOIMMUNE DISORDERS IN THE ACUTE SETTING Diagnosis and Treatment Goals Aimee Borazanci, MD BNI Neuroimmunology Objectives Give an update on the causes for admission, clinical features, and outcomes of
More informationThe role of pathology in the diagnosis of systemic vasculitis
Clinical and Experimental Rheumatology 2007; 25: S52-S56 The role of pathology in the diagnosis of systemic vasculitis J.C. Jennette 1, R.J. Falk 2 1 Brinkhous Distinguished Professor and Chair of Pathology
More informationPost-MDT leprosy neuropathy: differentially diagnosing reactional neuritis and relapses.
Sérgio Luiz Gomes Antunes Márcia Rodrigues Jardim Robson Vital Teixeira José Augusto da Costa Nery Anna Maria Sales, Euzenir Nunes Sarno Post-MDT leprosy neuropathy: differentially diagnosing reactional
More informationANCA associated vasculitis in China
ANCA associated vasculitis in China Min Chen Renal Division, Peking University First Hospital, Beijing 100034, P. R. China 1 General introduction of AAV in China Disease spectrum and ANCA type Clinical
More informationClinical Commissioning Policy: Rituximab For ANCA Vasculitis. December Reference : NHSCB/ A3C/1a
Clinical Commissioning Policy: Rituximab For ANCA Vasculitis December 2012 Reference : NHSCB/ A3C/1a NHS Commissioning Board Clinical Commissioning Policy: Rituximab For The Treatment Of Anti-Neutrophil
More informationDiagnostic Procedures for Vasculitis
Diagnostic Procedures for Vasculitis Toshiharu Matsumoto, MD Clinical Professor of Department of Diagnostic Pathology Juntendo University Nerima Hospital, Tokyo, Japan Introduction In 1994, the International
More informationThe European and French networks. Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France
The European and French networks Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France French Vasculitis Study Group December 1980: L. Guillevin no research,
More informationScleritis LEN V KOH OD
Scleritis LEN V KOH OD 2014 PUCO 1 Introduction A painful, destructive, and potentially blinding disorder Highly symptomatic High association with systemic disease Immunosuppresssive agents 2014 PUCO 2
More informationChurg Strauss syndrome and leukotriene antagonist use: a respiratory perspective
See Editorial, p 847 c Supplementary tables 1 4 and supplementary fig 1 are published online only at http:// thorax.bmj.com/content/vol63/ issue10 1 Department of Respiratory Medicine, City Hospital, Birmingham,
More informationChurg-Strauss Syndrome: Evolving Concepts
Discovery Medicine 243 Churg-Strauss Syndrome: Evolving Concepts Christian Pagnoux Abstract: Churg-Strauss syndrome is a rare, smallsized vessel systemic necrotizing vasculitis that was first described
More informationCHECK LIST FORM-MONTH 27 (Please note Month 27 is from enrolment not randomisation)
CHECK LIST FORM-MONTH 27 (Please note Month 27 is from enrolment not randomisation) Participant Initials: Date of Birth: Were the following forms completed for this visit? Follow Up Form Done t Done BVASWG
More informationComplicated Acute Motor Axonal Neuropathy with Delayed Acute Respiratory Distress Syndrome and Rapidly Progressive Glomerulonephritis: a Case Report
26 Complicated Acute Motor Axonal Neuropathy with Delayed Acute Respiratory Distress Syndrome and Rapidly Progressive Glomerulonephritis: a Case Report An-Chih Chen 1,6,7, Chiu-Mei Chen 1,6,7, Horng-Rong
More informationA Case of Sinobronchial Syndrome Complicated with Myeloperoxidase Antineutrophil Cytoplasmic Antibody Associated Vasculitis: Review of the Literature
CASE REPORT A Case of Sinobronchial Syndrome Complicated with Myeloperoxidase Antineutrophil Cytoplasmic Antibody Associated Vasculitis: Review of the Literature Toru Kadowaki 1, Shuichi Yano 1, Ichiro
More informationAccumulation of periostin in acute exacerbation of familial idiopathic pulmonary fibrosis
Case Report Accumulation of periostin in acute exacerbation of familial idiopathic pulmonary fibrosis Keisuke Murata 1, Yasuhiko Koga 1, Norimitsu Kasahara 1, Yoshimasa Hachisu 1, Satoshi Nunomura 2, Nozomi
More informationGRANULOMATOSIS WITH POLYANGIITIS
What is granulomatosis with polyangiitis (GPA)? Granulomatosis with polyangiitis (GPA) is a form of vasculitis a family of rare disorders characterized by inflammation of the blood vessels, which can restrict
More informationPrepared by Sarah Bozeman, MD, University of Mississippi Healthcare, and John Seyerle, Ohio State University
Allergy and Immunology Review Corner: Chapter 53 of Middleton s Allergy Principles and Practice, Seventh Edition, edited by N. Franklin Adkinson, et al. Chapter 53: Occupational Asthma Prepared by Sarah
More informationVasculitis (Polyarteritis Nodosa, Microscopic Polyangiitis, Wegener s Granulomatosis, Henoch- Schönlein Purpura)
Vasculitis (Polyarteritis Nodosa, Microscopic Polyangiitis, Wegener s Granulomatosis, Henoch- Schönlein Purpura) J. Charles Jennette Ronald J. Falk The kidneys are affected by a variety of systemic vasculitides
More informationCHECK LIST FORM-SCREENING
CHECK LIST FORM-SCREENING Participant Initials: Date of Birth: Evaluation Date: Were the following forms completed for this visit? Eligibility Form Done t Done Baseline medical History Form Done t Done
More informationTreatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome
Q J Med 2007; 100:41 51 doi:10.1093/qjmed/hcl125 Treatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome L. MATHEW 1, K. TALBOT 2, S. LOVE 3, S. PUVANARAJAH 2 and M. DONAGHY
More informationNIH Public Access Author Manuscript Ann Rheum Dis. Author manuscript; available in PMC 2011 July 19.
NIH Public Access Author Manuscript Published in final edited form as: Ann Rheum Dis. 2009 January ; 68(1): 103 106. doi:10.1136/ard.2008.097758. Comparison of disease activity measures for anti-neutrophil
More informationVASCULITIC SYNDROMES. Howard L. Feinberg, D.O., F.A.C.O.I., F.A.C.R. OPSC 2018
VASCULITIC SYNDROMES Howard L. Feinberg, D.O., F.A.C.O.I., F.A.C.R. OPSC 2018 2012 REVISED CHAPEL HILL CONSENSUS CONFERENCE Large vessel Takayasu arteritis Giant cell arteritis Medium Vessel Polyarteritis
More informationCase report. Open Access. Abstract
Open Access Case report Wegener s granulomatosis in which rheumatoid factor was useful for evaluating the disease status: a case report Hideto Oshita 1 *, Hiromi Matsumoto 2, Teppei Hoshino 2, Keitaro
More informationWegener s Granulomatosis JUN-KI PARK
Wegener s Granulomatosis JUN-KI PARK Definition History Epidemiology Clinical symptoms Pathophysiology Treatment Wegener granulomatosis (WG) is a complex, immunemediated disorder, which along with microscopic
More informationGlucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease
Article Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease JulieAnne G. McGregor, Susan L. Hogan, Yichun Hu, Caroline E. Jennette, Ronald J. Falk, and Patrick
More informationEvidence-based therapy for the ANCAassociated vasculitides: what do the trials. show so far? Clinical Trial Outcomes
associo far? Evidence-based therapy for the ANCAassociated vasculitides: what do the trials show so far? Anti-neutrophil cytoplasm antibody-associated vasculitides are rare multisystem inflammatory diseases
More informationCASE REPORT. Introduction
doi: 10.2169/internalmedicine.9188-17 http://internmed.jp CASE REPORT Diffuse Alveolar Hemorrhage Developing Immediately after Immunosuppressive Treatments in a Patient with Granulomatosis with Polyangiitis
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Injectable Asthma Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Injectable Asthma Agents Xolair (omalizumab) Prime Therapeutics will
More informationComplete Resolution of Dermatomyositis with Refractory Cutaneous Vasculitis by Intravenous Cyclophosphamide Pulse Therapy
CASE REPORT Complete Resolution of Dermatomyositis with Refractory Cutaneous Vasculitis by Intravenous Cyclophosphamide Pulse Therapy Shizuyo Tsujimura, Kazuyoshi Saito and Yoshiya Tanaka Abstract Cutaneous
More informationChurg Strauss syndrome (eosinophilic granulomatosis with polyangiitis): A case report
www.edoriumjournals.com CASE REPORT PEER REVIEWED OPEN ACCESS Churg Strauss syndrome (eosinophilic granulomatosis with polyangiitis): A case report M. West, P. Kumar ABSTRACT Churg Strauss syndrome (CSS)
More informationOptimizing the Therapeutic Strategies in ANCA-Associated Vasculitis Single Centre Experience with International Randomized Trials
Prague Medical Report / Vol. 107 (2006) No. 2, p. 199 212 199) Optimizing the Therapeutic Strategies in ANCA-Associated Vasculitis Single Centre Experience with International Randomized Trials Vaňková
More informationA rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis
Quan et al. BMC Pulmonary Medicine (2018) 18:181 https://doi.org/10.1186/s12890-018-0733-2 CASE REPORT Open Access A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
RITUXAN (rituximab) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
More informationPeripheral neuropathies, neuromuscular junction disorders, & CNS myelin diseases
Peripheral neuropathies, neuromuscular junction disorders, & CNS myelin diseases Peripheral neuropathies according to which part affected Axonal Demyelinating with axonal sparing Many times: mixed features
More informationThe systemic vasculitides were traditionally classified. Treatment of ANCA-associated Systemic Vasculitis. H. Michael Belmont, M.D.
60 Treatment of ANCA-associated Systemic Vasculitis H. Michael Belmont, M.D. Abstract The antineutrophil cytoplasmic antibodies (ANCA)-associated small vessel vasculitides include Wegener s granulomatosis,
More informationCase Presentation. Rafid Asfar, MD
Case Presentation Rafid Asfar, MD Introduction ANCA associated vasculitis may be localized or systemic, and can involve the eyes Ocular manifestations can occur in the absence of systemic disease in persons
More informationEosinophilic Granulomatosis with Polyangiitis (EGPA)- A presentation of rapid progressive demyelinating polyneuropathy
Open Journal of Clinical & Medical Case Reports Volume 3 (2017) Issue 25 ISSN 2379-1039 Eosinophilic Granulomatosis with Polyangiitis (EGPA)- A presentation of rapid progressive demyelinating polyneuropathy
More informationWegener s Granulomatosis
Wegener s Granulomatosis Authors: Professor Loïc Guillevin 1,2, Doctor Alfred Mahr Creation Date: May 2002 Update: January 2004 1 CHU Hôpital Cochin, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
More informationGranulomatosis with polyangiitis presenting as an orbital inflammatory pseudotumor: a case report
Isse et al. Journal of Medical Case Reports 2013, 7:110 JOURNAL OF MEDICAL CASE REPORTS CASE REPORT Open Access Granulomatosis with polyangiitis presenting as an orbital inflammatory pseudotumor: a case
More informationTREATMENT OF POLYARTERITIS NODOSA AND CHURG - STRAUSS SYNDROME. PROSPECTIVE THERAPEUTIC TRIALS
TREATMENT OF POLYARTERITIS NODOSA AND CHURG - STRAUSS SYNDROME. PROSPECTIVE THERAPEUTIC TRIALS CHUSPAN Coordination for PAN and CSS: Loïc Guillevin - Service de Médecine Interne - Hôpital Cochin, 27, rue
More informationFAQ Identifying and enrolling participants
FAQ Identifying and enrolling participants WHO IS ELIGIBLE - CASES? Patients with a new diagnosis of primary systemic vasculitis Patients suitable as cases are over 18 years with a new presentation or
More informationVascularites rénales associées aux ANCA
Vascularites rénales associées aux ANCA Société Médicale des Hôpitaux de Paris 16 Mars 2012 Philippe Vanhille Néphrologie et Médecine Interne Hôpital de Valenciennes Classification of systemic vasculitis:
More informationDisease flares, damage accrual and survival in ANCA-associated vasculitis in Western Australia
International Journal of Clinical Rheumatology Disease flares, damage accrual and survival in ANCA-associated vasculitis in Western Australia Background: ANCA-associated vasculitis (AAV) is a potentially
More informationChurg-Strauss Syndrome Concomitant with Chronic Symmetrical Dacryoadenitis Suggesting Mikulicz s Disease
CASE REPORT Churg-Strauss Syndrome Concomitant with Chronic Symmetrical Dacryoadenitis Suggesting Mikulicz s Disease Yusuke Hanioka 1, Keiko Yamagami 1, Katsunobu Yoshioka 2, Tomomi Nakamura 1, Masatsugu
More informationEosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
ARTHRITIS & RHEUMATISM Vol. 65, No. 1, January 2013, pp 270 281 DOI 10.1002/art.37721 2013, American College of Rheumatology Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Clinical Characteristics
More informationOverview. = inflammation of vessel wall. Symptoms and signs depend on the tissue of which the vessels are affected
Vasculitis (1+2) Overview = inflammation of vessel wall Symptoms and signs depend on the tissue of which the vessels are affected Often with systemic symptoms fever, myalgia, arthralgia, malaise etc. Most
More informationSevere Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy
doi: 10.2169/internalmedicine.1723-18 http://internmed.jp CASE REPORT Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy
More information